Ozempic-Like Drugs Spotlight Lateral Septum as Craving Center, Cutting Alcohol Use in 1 Study
Updated
Updated · ScienceDaily · Aug 12
Ozempic-Like Drugs Spotlight Lateral Septum as Craving Center, Cutting Alcohol Use in 1 Study
3 articles · Updated · ScienceDaily · Aug 12
Summary
GLP-1 agonists such as Ozempic appear to curb cravings for alcohol and other addictive substances by acting on the brain’s lateral septum, a region researchers now describe as a key reward-control hub.
The lateral septum is densely packed with GLP-1 receptors and links memory and place signals from the hippocampus with dopamine-driven reward circuits, helping turn thoughts about a reward into pursuit of it.
Recent evidence points to that mechanism directly: GLP-1 activation in the lateral septum reduced food intake in mice, and a study earlier this year found the same effect for alcohol consumption.
The finding shifts attention away from classic dopamine centers such as the ventral tegmental area and nucleus accumbens, which have relatively few GLP-1 receptors.
Researchers say the work could open new treatments for obesity, alcohol dependence and other substance-use disorders by targeting the neural circuitry of craving itself.
Could the same drug melting away pounds also rewire a hidden brain hub to erase deep-rooted addictions?
If an injection chemically dampens our cravings, what happens to our natural ability to experience everyday pleasure?
Semaglutide Cuts Heavy Drinking by 41%: The New Era of GLP-1 Drugs in Alcohol Use Disorder and Addiction Treatment
Overview
Recent clinical trials have shown that weekly semaglutide injections can greatly reduce heavy drinking days and alcohol intake in adults with alcohol use disorder (AUD) and obesity, while also improving liver health and supporting significant weight loss. These benefits are supported by large real-world studies showing lower risks of alcohol-related hospitalizations and substance use deaths among GLP-1 drug users. Scientists have discovered that these drugs work by activating GLP-1 receptors in the brain’s lateral septum, which helps quiet cravings. However, stopping the medication often leads to weight regain and a return of cravings, highlighting the need for long-term treatment and combined behavioral therapy for lasting recovery.